Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$0.75 - $1.26 $75,000 - $126,000
100,000 New
100,000 $75,000
Q1 2021

May 12, 2021

BUY
$9.26 - $14.36 $926,000 - $1.44 Million
100,000 New
100,000 $986,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track Twin Focus Capital Partners, LLC Portfolio

Follow Twin Focus Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Twin Focus Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Twin Focus Capital Partners, LLC with notifications on news.